177 related articles for article (PubMed ID: 28799510)
1. Safety Profile of the Newest Antiepileptic Drugs: A Curated Literature Review.
Palleria C; Cozza G; Khengar R; Libri V; De Sarro G
Curr Pharm Des; 2017; 23(37):5606-5624. PubMed ID: 28799510
[TBL] [Abstract][Full Text] [Related]
2. Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy.
Li-Na Z; Deng C; Hai-Jiao W; Da X; Ge T; Ling L
Epilepsy Res; 2018 Jan; 139():60-72. PubMed ID: 29197667
[TBL] [Abstract][Full Text] [Related]
3. Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison.
Zhu LN; Chen D; Xu D; Tan G; Wang HJ; Liu L
Seizure; 2017 Oct; 51():121-132. PubMed ID: 28854405
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.
Brigo F; Bragazzi NL; Nardone R; Trinka E
Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868
[TBL] [Abstract][Full Text] [Related]
5. Third generation antiepileptic drug monotherapies in adults with epilepsy.
Mula M
Expert Rev Neurother; 2016 Sep; 16(9):1087-92. PubMed ID: 27248204
[TBL] [Abstract][Full Text] [Related]
6. Timing use of novel anti-epileptic drugs: is earlier better?
de Biase S; Nilo A; Bernardini A; Gigli GL; Valente M; Merlino G
Expert Rev Neurother; 2019 Oct; 19(10):945-954. PubMed ID: 31257949
[No Abstract] [Full Text] [Related]
7. [Brivaracetam in the treatment of patients with epilepsy].
Karlov VA; Vlasov PN; Zhidkova IA; Kissin MY; Lebedeva AV; Lipatova LV; Mkrtchyan VR; Mukhin KY; Rudakova IG
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9. Vyp. 2):55-62. PubMed ID: 29213040
[TBL] [Abstract][Full Text] [Related]
8. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
9. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis.
Hu Q; Zhang F; Teng W; Hao F; Zhang J; Yin M; Wang N
J Neurol; 2018 Jan; 265(1):1-11. PubMed ID: 28940083
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
Patsalos PN; Berry DJ
Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of new antiepileptic drugs: a network meta-analysis.
Zaccara G; Giovannelli F; Giorgi FS; Franco V; Gasparini S; Benedetto U
Eur J Clin Pharmacol; 2017 Jul; 73(7):811-817. PubMed ID: 28378057
[TBL] [Abstract][Full Text] [Related]
14. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.
Chang XC; Yuan H; Wang Y; Xu HQ; Zheng RY
Cochrane Database Syst Rev; 2011 Dec; (12):CD008907. PubMed ID: 22161441
[TBL] [Abstract][Full Text] [Related]
15. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
16. Lacosamide for the treatment of epilepsy.
de Biase S; Gigli GL; Valente M; Merlino G
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):459-68. PubMed ID: 24479852
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs.
Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A
Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359
[TBL] [Abstract][Full Text] [Related]
18. Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.
Kwok CS; Johnson EL; Krauss GL
CNS Drugs; 2017 Nov; 31(11):959-974. PubMed ID: 29204953
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Antiepileptic Drugs in Patients with Focal Epilepsy: Systematic Review and Network Meta-analyses.
Campos MS; Ayres LR; Morelo MR; Marques FA; Pereira LR
Pharmacotherapy; 2016 Dec; 36(12):1255-1271. PubMed ID: 27779771
[TBL] [Abstract][Full Text] [Related]
20. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
